Dopamine D2 and serotonin 5-HT2A receptors (antagonist)

Assets acting on this target.

Class
atypical antipsychotic
Pathway
postsynaptic dopamine D2 and serotonin 5-HT2A receptor antagonism in mesolimbic and mesocortical pathways

Dopamine D2 and serotonin 5-HT2A receptors are G-protein-coupled receptors that atypical antipsychotics block simultaneously. D2 receptors are the primary site through which excess dopaminergic signaling in mesolimbic brain circuits is thought to produce the positive symptoms of psychosis, such as hallucinations and delusions; antagonizing D2 dampens this overactive signaling. Older antipsychotics relied on D2 blockade alone, which is effective against positive symptoms but tends to cause movement disorders and elevated prolactin because dopamine pathways elsewhere in the brain are also affected. Adding antagonism of 5-HT2A receptors, which normally restrain dopamine release in some of these same circuits, partially offsets that dopamine reduction outside the mesolimbic pathway, lowering the risk of movement-related side effects while preserving antipsychotic benefit. This dual-receptor strategy defines the 'atypical' class and is used broadly across schizophrenia, bipolar disorder, and related psychotic or mood conditions where dopaminergic and serotonergic signaling are dysregulated. The specific balance between D2 and 5-HT2A affinity varies across individual agents, shaping differences in efficacy and tolerability, but the underlying rationale, dampening excessive dopaminergic drive while limiting collateral effects through serotonergic modulation, is shared across the class.

By indication

Related mechanisms

Dopamine D2 and serotonin 5-HT2A receptors (antagonist) drugs compared

23 drugs, stage by indication
23 drugs acting on Dopamine D2 and serotonin 5-HT2A receptors (antagonist): developer, modality, furthest stage and stage in each indication. Furthest stage first.
DrugDeveloperModalityFurthest stageStage by indication
AsenapineAbbVie, Organonsmall moleculeApprovedApproved in Bipolar Disorder; Approved in Schizophrenia
ClozapineHLS Therapeutics Inc.small moleculeApprovedApproved in Schizophrenia
Iloperidone (Fanapt)FanaptVanda Pharmaceuticalssmall moleculeApprovedApproved in Bipolar Disorder; Approved in Schizophrenia
LurasidoneAngelini Pharma S.p.A. (A.C.R.A.F. S.p.A.), Sumitomo Pharmasmall moleculeApprovedApproved in Bipolar Depression; Approved in Schizophrenia
Milsaperidone (VHX-896)Vanda Pharmaceuticalssmall moleculeApprovedApproved in Bipolar Disorder; Approved in Schizophrenia; Phase 3 in Major Depressive Disorder
Olanzapine (Zyprexa Relprevv)Zyprexa RelprevvCheplapharm Arzneimittel GmbHsmall moleculeApprovedApproved in Schizophrenia
Olanzapine (Zyprexa)ZyprexaCheplapharm Arzneimittel GmbH, Eli Lillysmall moleculeApprovedApproved in Bipolar Disorder; Approved in Schizophrenia
Paliperidone (Invega)InvegaJohnson & Johnsonsmall moleculeApprovedApproved in Schizophrenia
Paliperidone palmitate (Erzofri)ErzofriLuye Pharma Groupsmall moleculeApprovedApproved in Schizophrenia
Paliperidone palmitate (Invega Sustenna)Invega SustennaJohnson & Johnsonsmall molecule (palmitate ester prodrug, long-acting injectable suspension)ApprovedApproved in Schizophrenia
Paliperidone palmitate (Invega Trinza)Invega Trinza / Invega HafyeraJohnson & Johnsonsmall molecule (palmitate ester prodrug, long-acting injectable suspension)ApprovedApproved in Schizophrenia
PerserisIndivior Pharmaceuticals, Inc.small moleculeApprovedApproved in Schizophrenia
Quetiapine (Seroquel XR)Seroquel XRAstraZeneca, Cheplapharm Arzneimittel GmbHsmall moleculeApprovedApproved in Bipolar Disorder; Approved in Major Depressive Disorder; Approved in Schizophrenia
Quetiapine (Seroquel)SeroquelCheplapharm Arzneimittel GmbH, Luye Pharma Groupsmall moleculeApprovedApproved in Bipolar Disorder; Approved in Schizophrenia
Risperidone (Risperdal Consta)Risperdal ConstaJohnson & Johnsonsmall moleculeApprovedApproved in Bipolar Disorder; Approved in Schizophrenia
Risperidone (Risperdal)RisperdalJohnson & Johnsonsmall moleculeApprovedApproved in Bipolar Disorder; Approved in Schizophrenia
Risperidone (Rykindo)RykindoLuye Pharma Groupsmall moleculeApprovedApproved in Bipolar Disorder; Approved in Schizophrenia
Risperidone (Uzedy)UzedyMedincell, Teva Pharmaceutical Industriessmall moleculeApprovedApproved in Bipolar Disorder; Approved in Schizophrenia
ZiprasidoneViatrissmall moleculeApprovedApproved in Bipolar Disorder; Approved in Schizophrenia
Loxapine (Adasuve)AdasuveFerrer Internacional, Lee's Pharmaceuticalsmall moleculePhase 3Phase 3 in Bipolar Disorder; Phase 3 in Schizophrenia
Olanzapine/samidorphan (Qilu)Qilu Pharmaceuticalsmall molecule combinationPhase 3Phase 3 in Schizophrenia
Risperidone (QUAR)Laboratorios Farmacéuticos Rovi, S.A.small moleculePhase 1Phase 1 in Schizophrenia
Paliperidone palmitate (CSPC)CSPC Pharmaceutical Groupsmall molecule (palmitate ester prodrug, long-acting injectable suspension); an independently-developed generic/biosimilar formulation, distinct from Janssen's Invega TrinzaStage not recordedNot recorded

← all mechanisms